Brokerages Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $3.80Zolmax • 19 days ago
ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) has been given a consensus rating of "Buy" by the four research firms that are covering the company, MarketBeat Ratings reports. Four investment...
Share to Feed
ProQR Therapeutics (NASDAQ:PRQR Get Free Report) had its target price lifted by Chardan Capital from $2.00 to $2.50 in a note issued to investors on Thursday, Benzinga reports. The brokerage...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further...
ProQR Therapeutics (NASDAQ:PRQR Get Free Report) has been assigned a consensus rating of Buy from the five research firms that are covering the company, Marketbeat Ratings...
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies...
ProQR Therapeutics (NASDAQ:PRQR Get Free Report) was upgraded by equities research analysts at StockNews.com from a hold rating to a buy rating in a report...
Shares of ProQR Therapeutics (NASDAQ:PRQR Get Free Report) have received a consensus recommendation of Buy from the five ratings firms that are covering the firm, Marketbeat...
ProQR Therapeutics (NASDAQ:PRQR Get Free Report) was downgraded by equities researchers at StockNews.com from a buy rating to a hold rating in a report released on...